Acarix USA, Inc will be at the American College of Cardiology ACC congress in Washington DC 2-4APR 2022. We are launching our FDA cleared diagnostic rule-out aid for suspected CAD patients with stable chest pain: CADScor®System.
Did you know that approximately 9 out of 10 patients assessed for Coronary Artery Disease do not have CAD? Millions of patients present with chest pain and suspected CAD each year!
FDA cleared diagnostic rule-out aid for suspected Coronary Artery Disease in patients with stable chest pain
Learn more about our innovative, FDA cleared, AI-powered CAD diagnostic aid at the ACC22, Future Hub booth FH11.
CADScor®System offers a simple, non-invasive aid to help rule out more than one third of these patients, potentially helping your team focus on the true root cause of symptoms, freeing up capacity for patients who need care, and decide on the next steps of the diagnostic pathway.
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.